InterCure Ltd. (NASDAQ:INCR) Short Interest Update

Posted by Andrew Walz on Feb 14th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 4,086 shares, a growth of 57.8% from the January 15th total of 2,590 shares. Based on an average trading volume of 46,481 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 46,481 shares, the short-interest ratio is currently 0.1 days.

InterCure Stock Up 1.1%

NASDAQ:INCR traded up $0.01 on Friday, reaching $0.90. The stock had a trading volume of 48,560 shares, compared to its average volume of 41,641. The company has a 50-day moving average of $1.05 and a 200 day moving average of $1.34. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.09 and a current ratio of 1.85. InterCure has a 12-month low of $0.68 and a 12-month high of $1.77.

InterCure (NASDAQ:INCR – Get Free Report) last released its quarterly earnings results on Wednesday, October 8th. The company reported ($0.02) EPS for the quarter. The company had revenue of $19.25 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InterCure in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, InterCure currently has a consensus rating of “Sell”.

Check Out Our Latest Report on InterCure

InterCure Company Profile

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.